Personalized Immune Cell Treatment NKCL Classic
NKCL Bio Group announced on the 31st that it has obtained both CE certification and KC certification on the 27th for ‘RK-NKTM ACS (hereinafter referred to as ACS-I)’, an automatic single-person NK cell cultivator released this year. CE certification is an integrated standard certification mark mean...
NKCL Bio Group Inc. won the grand prize in the NK cell therapy category at the 17th ‘Korea Health Industry Awards’ in 2023 The Korea Health Industry Award, which provides an opportunity to spread awareness about the importance of the health industry, raises its status, and boosts morale in the heal...
NKCL Bio Group announced that it had recently acquired a patent for a stimulant composition for rapid testing of natural killer cell activity and a test method using the same. Ph.D. Shin Dong-hyeok of NKCL Bio Group said, “Normally, NK cells in our body are inactive, but they are activated and respo...
NKCL Bio Group Inc. won the ‘2023 Customer Love Brand Grand Prize’ in the immune care platform category. |Growing into a global top bio company in the K-Bio field through immune care platform services On May 16th, NKCL Bio Group Inc., a bio company that researches and develops NK immune cell therap...
[2023 Customer Love Brand Award] Anti-aging solution ‘Just Ten Minutes’ is very popular NKCL Bio Group’s RK-NK100 anti-aging solution won the grand prize in the immune care platform category at the ‘2023 Customer Love Brand Awards’. The company holds patents and original technology for medium ad...
Acquired US patent for NK cell culture technology of NKCL Bio Group NKCL Bio Group (Chairman Shin Dong-hwa) announced that it had obtained a U.S. patent for NK cell culture technology. Recently, NKCL Bio Group successfully completed pre-clinical trials on the company's NK cell therapy pipeline for li...
[China-ROK (Changchun) International Cooperation Demonstration Zone Project, spurs the construction of a medical complex] A delegation from the 'China-ROK (Changchun) International Cooperation Demonstration Zone' (hereafter referred to as Changchun Demonstration Zone), an international industrial coo...
NKCL Bio Group, a high-tech biopharmaceutical manufacturing company, has obtained a cell processing facility permit under the Advanced Regenerative Bio Act from the Ministry of Food and Drug Safety(MFDS). Accordingly, NKCL Bio Group announced on the 24th that it will focus on the cell therapy busines...
NKCL Bio Group (Chairman Donghwa Shin), an advanced biopharmaceutical manufacturing company, announced on the 22nd that it had obtained permission for a cell processing facility based on the advanced regenerative bio method from the KFDA. NKCL Bio Group acquired permission to 'Manufacturing of Advanc...
As part of the policy pledge of the new government in 2022, in relation to fostering the advanced bioindustry, which is attracting attention as a growth engine industry, pharmaceutical and bio companies are announcing the latest biopharmaceutical manufacturing permits. This is interpreted as ‘legal ...
